Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT03370185 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

BRIO
Start date: February 12, 2018
Phase: Phase 2
Study type: Interventional

This is a multi-center, single-arm, open-label, Phase 2 study of duvelisib, an orally bioavailable dual inhibitor of PI3K-δ,γ, in patients with CLL/SLL who have previously been treated with ibrutinib or another Bruton's Tyrosine Kinase Inhibitor (BTKi) and relapsed or were refractory to such therapy or discontinued such therapy due to toxicity.

NCT ID: NCT03369964 Withdrawn - Clinical trials for Lymphoma, Non-Hodgkin

A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Start date: March 14, 2018
Phase: Phase 1
Study type: Interventional

This study will investigate the safety, pharmacology, and activity of atezolizumab in combination with immunotherapy agents with or without an anti-CD20 agent (i.e., obinutuzumab) in patients with relapsed or refractory (R/R) follicular lymphoma (FL). The first immunotherapy molecule investigated will be emactuzumab (Arm A) in two combinations.

NCT ID: NCT03367143 Active, not recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma Refractory

Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL

Start date: December 2016
Phase: Phase 2
Study type: Interventional

This study is to evaluate the efficacy and safety of Lenalidomide plus ICE in the treatment of Refractory and Relapsed DLBCL patients.

NCT ID: NCT03366272 Active, not recruiting - Clinical trials for Lymphoma, Non-Hodgkin

Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients

NIVEAU
Start date: December 5, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This study evaluates the addition of nivolumab to gemcitabine, oxaliplatin plus rituximab in case of B-cell lymphoma

NCT ID: NCT03365791 Completed - Clinical trials for Small Cell Lung Cancer

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Start date: January 24, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.

NCT ID: NCT03364439 Completed - Clinical trials for Diffuse Large B Cell Lymphoma

R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients

FIL_DLCL10
Start date: January 2012
Phase: Phase 2
Study type: Interventional

Prospective, multicentre phase II study with R-CHOP- 14 or R-CHOP-21 & consolidation PET-oriented radiotherapy (RT) in diffuse large B cell lymphoma (DLBCL) patients

NCT ID: NCT03364231 Completed - Clinical trials for Marginal Zone Lymphoma

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

Start date: November 30, 2017
Phase: Phase 2
Study type: Interventional

This research study will evaluate the safety and efficacy of a study drug called Umbralisib (also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia that has come back or that has not responded to standard treatment.

NCT ID: NCT03363555 Active, not recruiting - Clinical trials for Extranodal NK/T-cell Lymphoma, Nasal Type

SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma

Start date: May 29, 2018
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-center, nonrandomized, Phase 2 study to evaluate efficacy and safety of SHR-1210 in subjects with relapsed or refractory extranodal NK/T cell lymphoma.Efficacy will be assessed every 8 weeks according to 2014 Lugano criteria.Safety evaluations (both clinical and laboratory) are performed at baseline, before each study treatment, and throughout the study.

NCT ID: NCT03361852 Active, not recruiting - Follicular Lymphoma Clinical Trials

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

Start date: March 14, 2022
Phase: Phase 1
Study type: Interventional

This research study is studying a novel type of FL vaccine as a possible treatment for follicular lymphoma (FL). The agents involved in this study are: - Rituximab - Personalized NeoAntigen vaccine - Poly-ICLC - Pembrolizumab

NCT ID: NCT03361358 Completed - Lymphoma Clinical Trials

Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma

Start date: March 1, 2018
Phase:
Study type: Observational

The purpose of this study is to identify subjects with advanced solid tumors or lymphoma in which the methylthioadenosine phosphorylase (MTAP) protein has been lost.